Search Medical Condition
Please enter condition
Please choose location from dropdown

Roubaix Cedex 1, France Clinical Trials

A listing of Roubaix Cedex 1, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (627) clinical trials

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Collection of epidemiological data on non-high-risk APL patients aged 70 years: age and sex distribution, medical history, prognostic factors (time to treatment start, severity of coagulopathy at presentation, Performance status). Documentation of clinical and biologic effectiveness of the two first-line treatment approaches available for non-high-risk APL patients. Documentation of Minimal ...

Phase N/A

0.0 miles

Learn More »

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care

In the majority of European countries, the primary management of chronic heart failure patients is performed by General Practitioners in collaboration with cardiologists (specialists). Previous studies have shown that many patients suffering from CHF do not receive optimal pharmacological and/or device treatment for their disease. An increase in natriuretic peptides ...

Phase

0.0 miles

Learn More »

Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

INO schedule of administration will be as described in the refractory/relapsed INO-VATE study for the first cycle, with sequential day 1/8/15 doses of 0.8, 0.5 and 0.5 mg/m2, respectively. Reduced dose of INO will be used for the second and last cycle (0.5 mg/m2 on day 1/8). This was retained ...

Phase

0.0 miles

Learn More »

Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).

The study is presented during the first consultation of oncogeriatric care or after this consultation (for patients having benefited from the consultation between January 2014 and October 2014) : the patient is informed with an information note and is told that he can express its opposition to the use of ...

Phase N/A

0.0 miles

Learn More »

Innate Immunity Gene Polymorphisms and Yeast Colonization

Determination of the CIC: The CIC will be determined on admission and then once a week during hospitalisation. This will be carried out on a fixed day for all patients; we will avoid determining the CIC any closer than 2 days apart. It is not planned in this study to ...

Phase N/A

0.0 miles

Learn More »

Urinary Tract Infection Due to Beta-lactamase-producing Enterobacteriaceae in Children

In this prospective observational study between March 2013 and March 2017, children (0 to 18 years) with ESBL-E UTI were enrolled in 24 pediatric departments in France. Clinical and biological characteristics, risk factors of infection of E-ESBL, first and second lines of antibiotic therapies were analyzed. The investigators used the ...

Phase N/A

0.0 miles

Learn More »

Evaluation of a Regional Post-discharge Monitoring System for Suicide Attempters

Every patient who is discharged after a suicidal gesture will be proposed to enter the program. He will be handed a "green card" with a toll-free and unique phone number and an information letter which explains the program and his rights as a patient. Phone calls Calling team is composed ...

Phase N/A

0.0 miles

Learn More »

Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers

Reducing the time between the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) is essential to improve the vital prognosis and quality of life of patients. Recent data suggest that some sociocognitive and emotional determinants may explain patient delay from a complementary ...

Phase N/A

0.0 miles

Learn More »

High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment

RI is associated with poor prognosis and short median survival (32 months vs 55 months for MM patients with normal renal function). Thus, RI remains a major challenge for hematologists, including decisions on optimal anti-myeloma therapy, potential dialysis, supportive care and quality of life. The combination of a proteasome inhibitor ...

Phase N/A

0.0 miles

Learn More »

Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following ...

Phase

0.0 miles

Learn More »